Hospital
Weirton Medical Center, INC
Weirton Medical Center, INC was paid $27.68M by Medicaid between Jan 2018 and Dec 2024, across 300 billing codes. Its largest line is 99284, emergency room visit (serious) — 12% of everything it billed.
33Billing provider infoWEIRTON MEDICAL CENTER, INC
WEIRTON, WV 26062
WEIRTON, WV 26062
33aNPI1619921947assigned 05/20/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$27.68M
24GClaims694,258
24DCodes billed300
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in West Virginia
Rank by total paid#11 of 26
Median peer was paid$18.33M
This provider vs. median1.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 92,107 | $7.38M | |
| 2019 | 53,674 | $3.22M | |
| 2020 | 101,678 | $7.82M | |
| 2021 | 109,154 | $2.55M | |
| 2022 | 95,463 | $2.17M | |
| 2023 | 141,759 | $2.62M | |
| 2024incomplete | 100,423 | $1.93M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 25,051 | 22,327 | $3.24M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.8% | 28,815 | 26,421 | $2.72M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.5% | 8,586 | 7,365 | $2.64M |
| 96361 | Intravenous infusion, hydration; each additional hour | 5.8% | 16,773 | 11,510 | $1.62M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.4% | 18,763 | 16,187 | $668K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.4% | 55,309 | 42,538 | $661K |
| G0378 | Hospital observation service, per hour | 2.3% | 7,049 | 2,541 | $649K |
| 36592 | 2.1% | 20,921 | 17,574 | $581K | |
| 80053 | Comprehensive metabolic panel | 1.9% | 35,059 | 27,926 | $518K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.8% | 4,962 | 3,735 | $499K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.6% | 4,129 | 3,701 | $447K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.5% | 16,954 | 13,065 | $427K |
288 more codes
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.5% | 1,277 | $416K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.4% | 8,876 | $390K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.4% | 5,000 | $377K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.3% | 2,280 | $365K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.3% | 4,260 | $360K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.2% | 20,685 | $328K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.1% | 4,022 | $311K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.1% | 4,268 | $305K |
| 36415 | Collection of venous blood by venipuncture | 1.0% | 41,732 | $288K |
| 99213 | Doctor's office visit, returning patient (routine) | 1.0% | 5,460 | $286K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 11,328 | $256K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,388 | $255K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,706 | $239K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 3,452 | $226K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,176 | $225K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 10,220 | $216K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,385 | $198K |
| 84703 | <1% | 5,602 | $188K | |
| 96376 | <1% | 4,358 | $187K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 2,919 | $185K |
| 71045 | Radiologic examination, chest; single view | <1% | 8,099 | $183K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 6,429 | $169K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,114 | $168K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 4,409 | $168K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,808 | $167K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 590 | $158K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 996 | $152K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,096 | $148K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,719 | $145K |
| 87088 | <1% | 4,053 | $142K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,096 | $135K |
| 88342 | <1% | 1,363 | $134K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,380 | $133K |
| 80061 | Lipid panel | <1% | 6,892 | $125K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 2,600 | $115K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,695 | $114K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,749 | $110K |
| 81001 | <1% | 11,833 | $108K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 4,119 | $108K |
| 84484 | <1% | 6,706 | $108K | |
| 93041 | <1% | 1,150 | $108K | |
| 83690 | <1% | 8,135 | $105K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,111 | $103K |
| 83735 | <1% | 7,642 | $102K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 615 | $97K |
| 82550 | <1% | 5,868 | $95K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 218 | $92K |
| 85610 | <1% | 7,124 | $91K | |
| 82553 | <1% | 4,623 | $90K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 5,599 | $86K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,560 | $82K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 917 | $80K |
| 85027 | <1% | 4,474 | $79K | |
| 87081 | <1% | 2,711 | $76K | |
| 76830 | Ultrasound, transvaginal | <1% | 825 | $74K |
| 81002 | <1% | 3,040 | $73K | |
| 88304 | <1% | 169 | $72K | |
| 80076 | <1% | 4,633 | $71K | |
| 85730 | <1% | 4,828 | $70K | |
| 73610 | <1% | 999 | $67K | |
| 72110 | <1% | 810 | $63K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 765 | $62K |
| 84100 | <1% | 3,833 | $61K | |
| 93017 | <1% | 681 | $60K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,893 | $58K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,113 | $58K |
| 83880 | <1% | 1,896 | $57K | |
| 73630 | <1% | 1,222 | $57K | |
| 73562 | <1% | 1,077 | $56K | |
| 73120 | <1% | 795 | $56K | |
| 87040 | <1% | 1,764 | $54K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,038 | $53K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,111 | $52K |
| 80074 | <1% | 648 | $50K | |
| 84439 | <1% | 2,174 | $48K | |
| C1769 | Guide wire | <1% | 612 | $46K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,043 | $45K |
| 73030 | <1% | 1,366 | $44K | |
| 81003 | <1% | 2,349 | $44K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 388 | $44K |
| 88142 | <1% | 1,182 | $43K | |
| 62323 | <1% | 38 | $43K | |
| 82607 | <1% | 2,505 | $42K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,930 | $42K |
| 87186 | <1% | 2,622 | $41K | |
| 82728 | <1% | 3,112 | $39K | |
| 74018 | <1% | 847 | $38K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,030 | $37K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,168 | $37K |
| 87070 | <1% | 1,170 | $35K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,273 | $33K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 488 | $32K |
| 82803 | <1% | 510 | $31K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 291 | $30K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 71 | $29K |
| 85652 | <1% | 2,575 | $28K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,024 | $28K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 594 | $27K |
| 83550 | <1% | 2,385 | $27K | |
| 86140 | <1% | 1,821 | $26K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 311 | $26K |
| 82565 | <1% | 1,139 | $26K | |
| 97010 | <1% | 1,251 | $26K | |
| 80081 | <1% | 568 | $25K | |
| 83540 | <1% | 2,664 | $24K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 153 | $24K |
| 87077 | <1% | 2,216 | $24K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 157 | $23K |
| 87205 | <1% | 1,707 | $23K | |
| 86803 | <1% | 1,188 | $23K | |
| 97014 | <1% | 998 | $22K | |
| 84550 | <1% | 2,611 | $22K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 14 | $22K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,366 | $21K |
| 82150 | <1% | 867 | $21K | |
| 84520 | <1% | 974 | $21K | |
| 86038 | <1% | 667 | $21K | |
| 84702 | <1% | 1,152 | $20K | |
| 93970 | <1% | 160 | $20K | |
| 73110 | <1% | 413 | $20K | |
| 84153 | <1% | 682 | $19K | |
| 76642 | <1% | 236 | $18K | |
| 87631 | <1% | 397 | $17K | |
| 83605 | <1% | 1,003 | $17K | |
| 86618 | <1% | 408 | $16K | |
| 59025 | Fetal non-stress test | <1% | 230 | $16K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 149 | $16K |
| 94760 | <1% | 637 | $16K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 442 | $16K |
| 76801 | <1% | 204 | $15K | |
| 96367 | <1% | 340 | $15K | |
| 93971 | <1% | 316 | $15K | |
| 82746 | <1% | 1,080 | $15K | |
| 86756 | <1% | 305 | $14K | |
| 72131 | <1% | 353 | $14K | |
| 97162 | <1% | 151 | $14K | |
| 86900 | <1% | 1,015 | $13K | |
| 82570 | <1% | 1,361 | $13K | |
| 85379 | <1% | 847 | $13K | |
| 83615 | <1% | 1,555 | $13K | |
| 94060 | <1% | 110 | $13K | |
| 85018 | <1% | 1,067 | $12K | |
| 70486 | <1% | 97 | $12K | |
| 86850 | <1% | 735 | $12K | |
| 80050 | General health panel | <1% | 367 | $12K |
| 86308 | <1% | 235 | $11K | |
| 87147 | <1% | 444 | $11K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,319 | $11K |
| 71250 | <1% | 265 | $10K | |
| 87653 | <1% | 339 | $10K | |
| 95909 | <1% | 27 | $10K | |
| 86901 | <1% | 1,015 | $10K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 486 | $10K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 177 | $10K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 438 | $9K |
| 86769 | <1% | 860 | $9K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 276 | $8K |
| 84481 | <1% | 216 | $7K | |
| 73502 | <1% | 387 | $7K | |
| 93458 | <1% | 17 | $7K | |
| 74420 | <1% | 127 | $7K | |
| 94727 | <1% | 105 | $6K | |
| 74022 | <1% | 254 | $6K | |
| 82043 | <1% | 796 | $6K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 310 | $6K |
| 84460 | <1% | 427 | $6K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 320 | $6K |
| 84436 | <1% | 133 | $6K | |
| 94729 | <1% | 119 | $6K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 9,058 | $5K |
| 97161 | <1% | 272 | $5K | |
| 77065 | Tomosynthesis, mammo | <1% | 59 | $5K |
| 77066 | Tomosynthesis, mammo | <1% | 14 | $5K |
| 80320 | <1% | 352 | $5K | |
| 82248 | <1% | 344 | $4K | |
| 84403 | <1% | 150 | $4K | |
| 84207 | <1% | 51 | $4K | |
| 82950 | <1% | 337 | $4K | |
| 86665 | <1% | 44 | $4K | |
| 83655 | <1% | 140 | $4K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 13 | $3K |
| 52332 | <1% | 14 | $3K | |
| 99152 | <1% | 310 | $3K | |
| 76536 | <1% | 45 | $3K | |
| 76775 | <1% | 13 | $3K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,817 | $3K |
| 82948 | <1% | 112 | $2K | |
| 82140 | <1% | 188 | $2K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 74 | $2K |
| 86592 | <1% | 351 | $2K | |
| 86664 | <1% | 44 | $2K | |
| 93925 | <1% | 30 | $2K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 12 | $2K |
| 86762 | <1% | 195 | $2K | |
| 97165 | <1% | 99 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,874 | $2K |
| 84480 | <1% | 40 | $2K | |
| 97116 | <1% | 158 | $2K | |
| 86663 | <1% | 44 | $2K | |
| 82784 | <1% | 68 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,809 | $1K |
| 76770 | <1% | 25 | $1K | |
| 87808 | <1% | 236 | $1K | |
| 80051 | <1% | 35 | $1K | |
| 73080 | <1% | 55 | $1K | |
| 86430 | <1% | 28 | $1K | |
| 87340 | <1% | 271 | $1K | |
| 87905 | <1% | 255 | $1K | |
| 20552 | <1% | 15 | $1K | |
| 84156 | <1% | 251 | $1K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 192 | $1K |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 145 | $1K |
| 85045 | <1% | 299 | $1K | |
| 80143 | <1% | 157 | $960.54 | |
| 86060 | <1% | 43 | $952.21 | |
| 83970 | <1% | 37 | $952.02 | |
| 80179 | <1% | 127 | $894.62 | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 30 | $889.20 |
| 80164 | <1% | 31 | $879.85 | |
| 88313 | <1% | 30 | $823.27 | |
| 90715 | <1% | 48 | $790.60 | |
| 84450 | <1% | 75 | $779.09 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 156 | $773.24 |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 13 | $764.96 |
| 83516 | <1% | 17 | $742.13 | |
| 82962 | <1% | 878 | $733.92 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 137 | $725.46 |
| 81025 | <1% | 271 | $688.49 | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,448 | $647.00 |
| 72141 | <1% | 15 | $593.81 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 293 | $582.06 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 658 | $579.56 |
| 99153 | Mod sedat endo service >5yrs | <1% | 81 | $558.18 |
| 72050 | <1% | 27 | $534.36 | |
| 90686 | <1% | 21 | $526.10 | |
| 93922 | <1% | 13 | $471.30 | |
| 87522 | Neg quan hep c or qual rna | <1% | 12 | $462.72 |
| 10060 | <1% | 13 | $422.62 | |
| 84146 | <1% | 29 | $407.11 | |
| 72100 | <1% | 26 | $380.51 | |
| 73590 | <1% | 30 | $369.79 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,257 | $358.09 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 176 | $306.38 |
| 80348 | <1% | 267 | $296.93 | |
| 76937 | <1% | 19 | $295.60 | |
| 85014 | <1% | 45 | $295.48 | |
| 73564 | <1% | 67 | $284.85 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 776 | $271.38 |
| 80177 | <1% | 29 | $237.76 | |
| 72128 | <1% | 13 | $203.69 | |
| 73560 | <1% | 15 | $193.18 | |
| 84165 | <1% | 13 | $182.23 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 210 | $144.73 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 689 | $141.51 |
| 86431 | <1% | 27 | $128.44 | |
| 86200 | <1% | 14 | $122.58 | |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 108 | $115.62 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 462 | $109.20 |
| 73130 | <1% | 17 | $107.50 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 449 | $101.15 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 117 | $98.92 |
| 84145 | <1% | 14 | $98.00 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 165 | $91.55 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 270 | $68.09 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 213 | $67.59 |
| 82977 | <1% | 12 | $65.61 | |
| 82375 | <1% | 16 | $59.04 | |
| 83050 | <1% | 16 | $39.09 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 105 | $35.03 |
| G0379 | Direct admission of patient for hospital observation care | <1% | 43 | $31.81 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,611 | $29.09 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 51 | $17.12 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 353 | $13.24 |
| 36416 | <1% | 65 | $11.02 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 224 | $5.57 |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 26 | $4.81 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 359 | $2.61 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 20 | $2.30 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 17 | $2.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 76 | $0.55 |
| C1758 | Catheter, ureteral | <1% | 109 | $0.47 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 77 | $0.32 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 12 | $0.16 |
| 77300 | <1% | 20 | $0.06 | |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 75 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 122 | $0.00 |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | 0% | 22 | $0.00 |
| 00731 | 0% | 20 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBICKERS, JESSICA (MANAGER)